QTX125 (25-500 nM; 24-48 hours) treatment induces the subsequent apoptosis demonstrated by annexin V/propidium iodide double staining and the cleavage of caspase-9, caspase-8, caspase-3, and PARP[1]. In MCL cell lines MINO, REC-1, IRM-2 and HBL-2 cells, QTX125 (10 nM, 10 μM, 100 μM) induces dose-dependent hyperacetylation of α-tubulin[1].QTX125 has the strongest growth-inhibitory effect in Burkitt cell lymphoma, follicular lymphoma, and mantle cell lymphoma (MCL)[1].

QTX125 (60 mg/kg; i.p.; daily dosing for 5 days; for 4 weeks) treatment inhibits tumor growth in REC-1 or MINO cells xenografted in nude mice[1].